CV Therapeutics, Inc announced that the US Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa (ranolazine extended-release tablets) for the treatment of chronic angina. The new labelling also provides information showing that Ranexa reduced arrhythmias including ventricular arrhythmias, new onset atrial fibrillation and a potentially dangerous slow heartbeat known as bradycardia in patients with coronary artery disease. In addition, the new labeling states that Ranexa reduces haemoglobin A1c (HbA1c) in patients with diabetes.
According to the revised labelling, Ranexa is indicated for the treatment of chronic angina and may be used alone or in combination with traditional therapies for chronic angina, such as beta blockers, calcium channel blockers and nitrates, and common cardio-protective treatments for cardiovascular disease such as anti-platelet therapy, lipid-lowering therapy, ACE inhibitors and angiotensin receptor blockers.
Ranexa may now be used as part of an optimal medical therapy regimen for chronic angina patients, regardless of whether or not they receive a stent or other medical intervention. Ranexa does not reduce heart rate or blood pressure and, unlike long acting nitrates, Ranexa can be prescribed for patients taking oral erectile dysfunction treatments.
"This important FDA action allows the benefits of Ranexa to be extended to more patients. The new labelling clearly describes the substantial proven safety and efficacy of Ranexa for the treatment of chronic angina, the debilitating cardiac chest pain that affects more than nine million Americans each year," said Louis G Lange, CV Therapeutics chairman and chief executive officer.
"Ranexa is a very well tolerated drug that can now be considered among the first drugs to be given to patients with chronic angina. Our commercial organization will actively focus on educating new and existing prescribers about these significant new labeling improvements," Lange added.
"Ranolazine may now take optimal medical therapy to an entirely new level, and may afford enhanced symptom relief," said Dr William Boden, clinical chief, division of cardiovascular medicine, University at Buffalo Schools of Medicine & Public Health and principal investigator of the courage study. "I have seen excellent safety, tolerability and symptom relief in the great majority of chronic angina patients for whom I have prescribed ranolazine," he added.
"As we have seen in the Merlin-Timi 36 trial and in clinical practice, patients with ischemia and angina can be at increased risk for arrhythmias and also often have diabetes. Considering its mechanism of action, established cardiovascular safety and observed reductions in arrhythmias and HbA1c, ranolazine now becomes an even more important drug in our treatment of chronic angina," said Dr Eugene Braunwald, Distinguished Hersey Professor of Medicine at Harvard Medical School and chairman of the TIMI Study Group.
These significant new labelling changes were supported by a supplemental new drug application submitted in September 2007 that included data from the 6,560 patient Merlin-Timi 36 trial, which showed no adverse trend in death or arrhythmia in a high risk acute coronary syndromes patient population.
The revised labelling includes new language noting that there was a significantly lower incidence of arrhythmias (ventricular tachycardia, bradycardia, supraventricular tachycardia and new atrial fibrillation) in patients treated with Ranexa versus placebo. This difference in arrhythmias did not lead to a reduction in mortality, a reduction in arrhythmia hospitalization or a reduction in arrhythmia symptoms.
The revised labelling also includes new language noting that Ranexa produces small reductions in HbA1c. Though Ranexa should not be considered a treatment for diabetes, Ranexa may be a particularly useful medication for the reduction of chronic angina in this patient population, which is difficult to treat because some anti anginal medications such as beta blockers increase HbA1c.
In the United Sates, Ranexa is indicated for the treatment of chronic angina. Ranexa may be used with beta blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, and ACE inhibitors.
CV Therapeutics, Inc, headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.